A Scottish cystic fibrosis patient who wrote goodbye letters to her family before a revolutionary drug saved her life has ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Avery Stromeyer was diagnosed with cystic fibrosis when she was just nine days old, but that isn’t something the now ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

A Clydebank cystic fibrosis patient who wrote goodbye letters to her family before a revolutionary drug saved her life has turned her ordeal ...

EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, ...